Volume : 10, Issue : 05, May – 2023
02.A REVIEW ON DIABETIC NEPHROPATHY
Jyothi B N*, Mrs. Soumya R V, Ms. Liya S Saji, Ms. Revathi Mohan, Dr. Prasobh G R Sree
Diabetic nephropathy (DN) is a serious complication of type 1 diabetes and type 2 diabetes. It’s also called diabetic kidney disease. It is one of the most feared diabetic chronic microvascular complications and the major cause of end-stage renal disease (ESRD). The classical presentation of DN is characterized by hyperfiltration and albuminuria in the early phases which is then followed by a progressive renal function decline. Diabetic nephropathy or diabetic kidney disease is a syndrome characterized by the presence of pathological quantities of urine albumin excretion, diabetic glomerular lesions, and loss of glomerular filtration rate (GFR) in diabetics.
Cite This Article:
Please cite this article in press Jyothi B N et al, A Review On Diabetic Nephropathy., Indo Am. J. P. Sci, 2023; 10 (05).
Number of Downloads : 10
1. Harsh Mohan. Text book of pathology .3rd edition. page no.681.
2. Laporte RE et al. prevalence and incidence of insulin- dependent diabetes. In: Harris MI et al., eds.
3. Diabetes in America. 2nd Ed. Bethesda, MD: National Institutes of Health,1995: 37.NIH publication No. 95-1468.
4. DR. Madan Kaushik. Text book of pathophysiology Page no. 217.
5. Harsh Mohan. Text book of pathology .3rd edition. page no.681.
6. DR. Madan Kaushik Text book of pathophysiology Page no. 217.
7. WebMD Medically Reviewed by Michael Dansinger, MD on November 06, 2020
8. Koda-Kimble & Young’s Applied therapeutics the clinical use of drug tenth edition by page no. 1227.
9. Joseph T Dipiro, Barbara Wells, Teerry L. Schwinghammer, Pharmacotherapy handbook 9th edition. page no.162-169.
10. Roger- walker and cate Whittlesea. Clinical pharmacy and therapeutics page no. 693-695
11. Roger- walker and cate Whittlesea. Clinical pharmacy and therapeutics page no.612.
12. Roger- walker and cate Whittlesea. Clinical pharmacy and therapeutics. page no.706.
13. Harsh Mohan Text book of pathology.3rd edition. page no.561-562
14. Viswanathan m, Snehlata C, Bhattacharya PK, et al. micro albuminuria in NIDDM patients in south India. India J Med res (B);1991,94: page no.125-129.
15. Gupta LK, Verma LK, Khosla PK, Dash SC. The prevalence of microalbuminuria in Indian diabetics. Ind J Nephrol 1991; 1:61.
16. Medically reviewed by Deborah Weatherspoon, Ph.D., msn- by tom Seymour.
17. American diabetes association: nephropathy in diabetes. Diabetes care 27(suppl.1): S79- S83,2004.
18. Adler AI, Stevens R J, Manley SE: development and progression of nephropathy in type 2 diabetes: Kidney int 63:225-232, 2003.
19. J Diabetes Invest, Doi: 10.1111/j.2040‐1124.2011. 00131.x, 2011.
20. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 1998; 352: 213–219 [PubMed] [Google Scholar].
21. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957–1972 [PubMed] [Google Scholar].
22. International journal of nephrology and renovascular disease by Andy KH Lim.
23. McGill M, Blonde L, Chan JCN, Khunti K, Lavalle FJ, Bailey CJ., Global Partnership for Effective Diabetes Management. The interdisciplinary team in type 2 diabetes management: Challenges and best practice solutions from real-world scenarios. J Clin Trans Endocrinol. 2017 Mar; 7:21-27. [PMC free article] [PubMed].
24. Mahnensmith RL, Zorzanello M, Hsu YH, Williams ME. A quality improvement model for optimizing care of the diabetic end-stage renal disease patient. Semin Dial. 2010 Mar- Apr;23(2):206-13. [PubMed].
25. Shen ZZ, Huang YY, Hsieh CJ. Early short-term intensive multidisciplinary diabetes care: A ten-year follow-up of outcomes. Diabetes Res Clin Pract. 2017 Aug; 130:133-141. [PubMed].